In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Juno Therapeutics Inc. (NASDAQ:JUNO) reported that Bratton Douglas K has picked up 9,348,799 of common stock as of 2017-07-18.
The acquisition brings the aggregate amount owned by Bratton Douglas K to a total of 9,348,799 representing a 8.8% in the company.
For those not familiar with the company, Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Its product candidates JCAR017, JCAR014, and JCAR015, as well as an additional early stage product candidate incorporating a fully human binding domain, leverage CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas. Its CAR product candidate JCAR018 targets CD22, a different protein commonly expressed on the surface of B cell leukemias and lymphomas. Its MUC-16 directed product candidate is an armored CAR that secretes the cytokine interleukin 12 (IL-12), which may help to overcome the inhibitory effects that the tumor microenvironment can have on T cell activity..
A glance at Juno Therapeutics Inc. (NASDAQ:JUNO)’s key stats reveals a current market capitalization of 2.93 Billion based on 106.10 Million shares outstanding and a price at last close of $27.55 per share.
Looking at insider activity, there are a few recent transactions worth noting.
Specifically, on 2017-06-20, Evnin picked up 9,000 at a purchase price of $24.40. This brings their total holding to 66,301 as of the date of the filing.
On the sell side, the most recent transaction saw Bratton unload 8,000,000 shares at a sale price of $27.00. This brings their total holding to 9,166,130.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above.
We’ll be keeping an eye on Juno Therapeutics Inc. (NASDAQ:JUNO) as things move forward to see if its progress aligns with these transactions. Subscribe below and we’ll keep you on top of what’s happening before it moves markets.